U.S. Stocks Buzz: Range Resources Corp. (RRC), Endo International plc – Ordinary Shares (ENDP)


Range Resources Corp. (NYSE:RRC)

Stock’s Trading Stats:

Range Resources Corp. (NYSE:RRC) is trading up with a percentage change of 0.57% and is at $37.19 right now. The Company’s market capitalization stands at $6.18 Billion in the current trading Session whereas, its outstanding shares are 169.74 Million.

Recent Press Release:

Range Resources Corp. (RRC) on March 28, 2016 declared that it has accomplished the sale of its Bradford County non-operated assets. After purchase price adjustments based upon a January 1st effective date, Range received about $110 million of sales proceeds at the closing plus retaining the net cash flow since the effective date. In early February, Range signed a purchase and sale agreement covering its non-operating Marcellus interest in Bradford County, Pennsylvania for about $112 million. Range sold an average working interest of 23% covering about 10,900 net acres with net production of about 22 Mmcf per day.

Range will include the Bradford County operations in its operations until the closing date in its first quarter stated operations. The net proceeds were used to reduce debt and other corporate purposes. This monetization further strengthens the Company’s financial position by reducing leverage and enhancing liquidity. After the sale, the borrowing base under Range’s revolving credit facility remains unchanged at $3 billion.

Endo International plc – Ordinary Shares (NASDAQ:ENDP)

Stock’s Trading Stats:

Endo International plc – Ordinary Shares (NASDAQ:ENDP) is declining -2.65% percent and is at $26.45 in the Real-Time trading session. The stock’s market capitalization stands at $6.03 Billion with outstanding shares of 22.14 Million.

Recent Press Release:

Endo International plc – Ordinary Shares (ENDP) on March 21, 2016 offered a statement and a Frequently Asked Questions (FAQs) document regarding the predictable approval by the U.S. Food and Drug Administration of a competitor’s generic version of Voltaren Gel (diclofenac sodium topical gel) 1%.

Endo is evaluating a number of options regarding Voltaren® Gel focused on evolving its branded product strategy, determining the timing of a potential Authorized Generic product launch and maximizing overall value. The Company will provide additional detail regarding the potential financial impact of a generic entrant for Voltaren® Gel no later than its first quarter 2016 earnings presentation in early May 2016.